Molecular targeted therapy Binding Mode Gefitinib Dosage and Usage Clinical evaluation Adverse reactions and precautions What is molecular targeted therapy?
ChemicalBook > CAS DataBase List > Erlotinib

Erlotinib

Molecular targeted therapy Binding Mode Gefitinib Dosage and Usage Clinical evaluation Adverse reactions and precautions What is molecular targeted therapy?
Product Name
Erlotinib
CAS No.
183321-74-6
Chemical Name
Erlotinib
Synonyms
ERLOTINIB HCL;Tarceva;Erlortinib;R 1415;Rotini;OSI 744;Erlonat;ERLOTININ;ERLOTINIB;NSC-71878
CBNumber
CB9285914
Molecular Formula
C22H23N3O4
Formula Weight
393.44
MOL File
183321-74-6.mol
More
Less

Erlotinib Property

Melting point:
159-160 °C
Boiling point:
553.6±50.0 °C(Predicted)
Density 
1.24
storage temp. 
Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility 
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
form 
Solid
pka
5.32±0.30(Predicted)
color 
White
CAS DataBase Reference
183321-74-6(CAS DataBase Reference)
More
Less

Safety

Safety Statements 
24/25
HS Code 
29335990
Hazardous Substances Data
183321-74-6(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H227Combustible liquid

H304May be fatal if swallowed and enters airways

H350May cause cancer

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P308+P313IF exposed or concerned: Get medical advice/attention.

P331Do NOT induce vomiting.

P370+P378In case of fire: Use … for extinction.

P403+P235Store in a well-ventilated place. Keep cool.

P405Store locked up.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
10483
Product name
Erlotinib
Purity
≥98%
Packaging
1g
Price
$98
Updated
2024/03/01
Cayman Chemical
Product number
10483
Product name
Erlotinib
Purity
≥98%
Packaging
5g
Price
$426
Updated
2024/03/01
Cayman Chemical
Product number
10483
Product name
Erlotinib
Purity
≥98%
Packaging
250mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
10483
Product name
Erlotinib
Purity
≥98%
Packaging
500mg
Price
$57
Updated
2024/03/01
ChemScene
Product number
CS-0620
Product name
Erlotinib
Purity
99.99%
Packaging
1g
Price
$60
Updated
2021/12/16
More
Less

Erlotinib Chemical Properties,Usage,Production

Molecular targeted therapy

The small molecule compound, Erlotinib is a receptor tyrosine kinase inhibitor (EGFR antagonist) and belongs to molecular targeted therapy Drugs. It can inhibit the phosphorylation reaction through competing with adenosine triphosphate to bind to the catalytic region of the receptor tyrosine kinase, thereby blocking the down-proliferation signaling and inhibiting the activity of the tumor cell ligand-dependent HER-1/EGFR, thus achieving the inhibition of the proliferation of tumor cells. Clinically, it is mainly used in the treatment of incurable locally advanced or metastatic non-small cell lung cancer (NSCLC) and being used in combination with gemcitabine for first-line treatment of locally advanced unresectable or metastatic pancreatic cancer.
In November 2004, the product was first approved in the United States for the treatment of local advanced or metastatic non-small cell lung cancer (NSCLC) which has been undergone at least one time of chemotherapy failure.
In 2005, the results of a Phase III trial of the NCI Canadian Clinical Trials Group suggested that gemcitabine, in combination with erlotinib (EGFR blocker) can increase the median survival of patients with advanced pancreatic cancer from 5.9 months to 6.4 months and 1-year survival from 17% to 24%.
In November 2005, Genentech and OSI jointly announced that the US Food and Drug Administration (FDA) had approved the combination of erlotinib (Tarceva) and gemcitabine as first-line treatment for advanced pancreatic cancer.

Binding Mode

Erlotinib binds to the ATP-binding pocket of active EGFR as a type I inhibitor. At the same time, it behaves as a type I1/2 inhibitor in binding to the inactive DFG-in and C helix-out conformation. In both co-crystal structures, the quinazoline N1 hydrogen bonds with the amide nitrogen of Met769 in the hinge region, while the N3 is interacting indirectly with the side chain hydroxyl of Thr766 via a bound water molecule.

Gefitinib

Gefitinib is an aniline quinazoline derivative and is also a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that inhibits the growth, metastasis and angiogenesis of tumors and increases tumor cell apoptosis;
Gefitinib is a kind of highly-specific anti-tumor targeted therapy drugs developed by the United Kingdom AstraZeneca, being the first molecular targeted drug for the treatment of non-small cell lung cancer. It takes effects through selectively inhibiting the signal transduction pathway of the epidermal growth factor receptor tyrosine kinase (EGFR-TK). Epidermal growth factor (EGF) is a polypeptide with a relative molecular mass of 6.45 × 103 that binds to the epidermal growth factor receptor (EGFR) on the target cell membrane to produces biological effects. EGFR is a tyrosine kinase (TK) receptor that, when conjugated to EGF, being capable of promoting the TK activation in the receptor, leading to auto-phosphorylation of the receptor tyrosine residue, providing a continuous signal splitting into the cell, further causing cell proliferation and differentiation. EGFR is abundant in human tissues and highly expressed in malignant tumors. Gefitinib, through interfering with the EGFR signaling transduction pathways on the cell surface, inhibits the tumor growth, metastasis and angiogenesis and induces tumor cell apoptosis.
In August 2002, gefitinib, as a first-line treatment of non-small cell lung cancer drugs, was first listed in Japan under the trade name of Iressa.
In May 2003, the US Food and Drug Administration approved gefitinib as the three-line monotherapy drug for patients with advanced non-small cell lung cancer that can’t be cured by platinum-based anti-cancer drugs and docetaxel chemotherapy. Now, it has been also approved by Australia, Japan, Argentina, Singapore and South Korea and other countries for the treatment of advanced non-small cell lung cancer.
On February 28, 2005, the Chinese Food and Drug Administration approved gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) previously subjecting to chemotherapy treatment. It has not yet been approved as a first-line treatment for advanced NSCLC.
On July 1, 2009, the European Union Drug Administration has formally approved gefitinib for the first, second and third line treatment of adult EGFR mutations locally advanced or metastatic non-small cell lung cancer.

Dosage and Usage

Non-small cell lung cancer: 150mg/d; administrate at least1h before meals or 2h after meal; continue taking the drug until the disease get progression or the emergence of intolerable toxicity response when the patients should withdraw the drug.
Pancreatic cancer: combine with gemcitabine for 100mg /d at least 1h before meals or 2h after meals; continue taking the drug until the disease get progression or the emergence of intolerable toxicity response when the patients should withdraw the drug.
Upon severe liver insufficiency, the drug dosage should be reduced or temporarily discontinued, elderly patients do not have to adjust the dose.

Clinical evaluation

Erlotinib is another tyrosine kinase inhibitor for the treatment of NSCLC after imatinib. The phase I clinical trial results have shown that its main toxicity and side effects are dose-dependent rash and diarrhea. Other rare side effects also include headache, nausea and vomiting.
Phase II trial takes erlotinib as a second line antineoplastic drugs with the efficacy being comparable as the second-line chemotherapy drug docetaxel. The Phase III randomized controlled trial (BR21) was performed in patients with NSCLC who had failed in the primary or secondary chemotherapy (locally advanced and distant metastases). Study group applied erlotinib in a dosage of 150mg daily for treatment of a total of 488 cases. A total of 243 cases were treated with placebo in the control group. The result: the median overall survival rate was 6.7 months in the treatment group and 4.7 months in the control group (P <0.001, HR = 0.73). The 1-year survival rate was 31.2% in the treatment group and 21.5% in the control group; the time of progression was 9.9 weeks in treatment group and 7.9 weeks in control group while the improvement of symptoms in patients with erlotinib was more obvious.
Based on the results of BR21 research, a number of phase Ⅲ clinical studies have been carried out successively. TRIBUTE clinical trial combined the Erlotinib with chemotherapy in an attempt to compare whether the efficacy of its combination with chemotherapy is better than chemotherapy alone. For the treatment group, chemotherapy (carboplatin plus paclitaxel) + erlotinib were combined; for the control group, the same chemotherapy was used alone. A total of 1059 patients with advanced NSCLC were included in the study. The efficacy in the research result: 21.5% for research group; 19.3% for the control group. The median survival time was 10.8 months in the study group and 10.6 months in the control group. The time to tumor progression (TTP) was 5.1 months in the study group and 5.0 months in the control group. Another TALENT study also focused on whether the combination of erlotinib and chemotherapy (gemcitabine + cisplatin) can improve the efficacy of chemotherapy and have included a total of 1172 cases of NSCLC patients. The results also did not show that erlotinib can significantly improve the efficacy of chemotherapy.

Adverse reactions and precautions

Common adverse reactions include rash, fever, anorexia, indigestion, nausea, vomiting, diarrhea, constipation and abdominal pain, fatigue, weight loss and edema, bone pain and muscle pain, dyspnea, elevated transaminases. In rare cases, it was observed of bone marrow suppression. Oral administration of warfarin may lead to unexpectedly increased international standardization ratio. There are occasionally chills, cough, stomatitis, keratoconjunctivitis, anxiety and neurological diseases, elevated bilirubin. In rare cases, there are microangiopathies hemolytic anemia and thrombocytopenia. Cough and fever may be associated with interstitial lung disease, if it occurs, the drugs should be discontinued. Cytochrome P450 enzymes affect the metabolism of the product. Its inhibitor ketoconazole or agonist rifampicin can change the plasma concentration of this product, resulting in increased toxicity or reduced toxicity. Patients of co-administration of warfarin should subject to closely monitoring of the international normalized ratio.

What is molecular targeted therapy?

Molecular targeted therapy is no longer a new term. Scientists are constantly exploring the pathogenesis of cancer molecular biology, realizing that if specific changes in cancer can be given by a powerful blow, it will greatly improve the treatment effect, triggering changes in anti-cancer treatment concept. In recent years, new molecular targeted drugs in clinical practice have achieved remarkable results. The practice has shown that the correctness and feasibility of the molecular targeted therapy theory, putting the cancer treatment to an unprecedented new stage.
Depending on the target and nature of the drug, the drugs of the major target molecule therapy can be divided into the following categories:
(1) Small molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR): such as gefitinib (Iressa), Erlotinib (Tarceva);
(2) anti-EGFR monoclonal antibody: such as cetuximab ();
(3) Anti-HER-2 monoclonal antibody: such as Herceptin (Trastuzumab);
(4) Bcr-Abl tyrosine kinase inhibitors: such as imatinib;
(5) Vascular endothelial growth factor receptor inhibitors: such as Bevacizumab (Avastin);
(6) anti-CD20 monoclonal antibody: such as rituximab (Rituximab);
(7) IGFR-1 kinase inhibitors such as NVP-AEW541;
(8) mTOR kinase inhibitors: such as CCI-779;
(9) Ubiquitin-proteasome inhibitors: such as Bortezomib;
(10) Other: such as Aurora kinase inhibitors, histone deacetylase (HDACs) inhibitors.

Description

Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.

Uses

Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM.

Uses

antineoplastic;tyrosine kinase inhibitor

Uses

A tyrosine kinase inhibitor

Definition

ChEBI: A quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.

brand name

Tarceva (OSI).

General Description

Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 60%
Elimination half-life = 36 h
Protein binding = 93%

Clinical Use

Erlotinib
Treatment of locally advanced or metastatic nonsmall cell lung cancer after failure of at least 1 other regime
Pancreatic cancer

Side effects

  • Burning, tingling, numbness or pain in the hands, arms, feet, or legs.
  • cough or hoarseness.
  • diarrhea (severe)
  • difficult or labored breathing.
  • fever or chills.
  • rash (severe)
  • sensation of pins and needles.
  • stabbing chest pain.

Synthesis

The synthesis of Erlotinib is as follows:
N-dimethylformamidine, 0.72 g (6.15 mmol) of N '- [2-cyano-4,5-bis (2-methoxyethoxy) phenyl] ) Of 3-aminophenylacetylene and 8 mL of acetic acid were reacted in a 50 mL reaction flask at 125 ° C for 1 hour and cooled to room temperature.20 mL of ice water was added to the mixture, the pH was adjusted to 10 with aqueous ammonia, and the mixture was stirred for 1 hour, suction filtered and the filter cake washed with water until neutral.The filter cake was dried to obtain 2.15 g of erlotinib in a yield of 91.5%.

Drug interactions

Potentially hazardous interactions with other drugs Analgesics: increased risk of bleeding with NSAIDs.
Antacids: concentration possibly reduced by antacids, give at least 4 hours before or 2 hours after erlotinib.
Anticoagulants: increased risk of bleeding with coumarins
Antipsychotics: avoid concomitant use with clozapine, increased risk of agranulocytosis.
Antivirals: avoid with boceprevir.
Ulcer-healing drugs: avoid with cimetidine, esomeprazole, famotidine, lansoprazole, nizatidine, pantoprazole and rabeprazole; concentration reduced by ranitidine, give at least 2 hours before or 10 hours after ranitidine; concentration reduced by omeprazole - avoid.

Metabolism

Erlotinib is metabolised mainly by the cytochrome P450 isoenzyme CYP3A4, and to a lesser extent by CYP1A2. Extrahepatic metabolism by CYP3A4 in intestine, CYP1A1 in lung, and 1B1 in tumour tissue potentially contribute to the metabolic clearance of erlotinib.
Metabolic pathways include demethylation, to metabolites OSI-420 and OSI-413, oxidation, and aromatic hydroxylation. The metabolites OSI-420 and OSI-413 have comparable potency to erlotinib in non-clinical in vitro assays and in vivo tumour models. They are present in plasma at levels that are <10 % of erlotinib and display similar pharmacokinetics as erlotinib. Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose. Less than 2% of the orally administered dose is excreted as parent substance

Erlotinib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Erlotinib Suppliers

China 375 China Hong Kong 1 Europe 1 Germany 2 India 19 Israel 1 Spain 1 The Netherlands 1 United Kingdom 6 United States 34 Global 441
LGM Pharma
Tel
1-(800)-881-8210
Fax
615-250-9817
Email
inquiries@lgmpharma.com
Country
United States
ProdList
2123
Advantage
70
MedChemexpress LLC
Tel
021-58955995
Fax
609-228-5909
Email
sales@medchemexpress.cn
Country
United States
ProdList
4861
Advantage
58
HBCChem, Inc.
Tel
+1-510-219-6317
Fax
+1-650-486-1361
Email
sales@hbcchem.com
Country
United States
ProdList
10648
Advantage
60
Target molecule Corp.
Tel
857-239-0968
Fax
857-239-8801
Email
service1@targetmol.com
Country
United States
ProdList
2559
Advantage
60
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
Country
United States
ProdList
32165
Advantage
58
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Fax
708-557-7486
Email
sales@invivochem.cn
Country
United States
ProdList
6391
Advantage
58
Accela ChemBio Inc.
Tel
+1-858-6993322
Fax
(+1)-858-876-1948
Email
info@accelachem.com
Country
United States
ProdList
17322
Advantage
58
BOC Sciences
Tel
+1-631-485-4226
Fax
1-631-614-7828
Email
inquiry@bocsci.com
Country
United States
ProdList
19553
Advantage
58
TargetMol Chemicals Inc.
Tel
+8613564774135
Email
zijue.cai@tsbiochem.com
Country
United States
ProdList
19885
Advantage
58
TargetMol Chemicals Inc.
Tel
Email
support@targetmol.com
Country
United States
ProdList
38632
Advantage
58
Aladdin Scientific
Tel
+1-+1(833)-552-7181
Email
sales@aladdinsci.com
Country
United States
ProdList
57505
Advantage
58
United States Biological
Tel
--
Fax
--
Email
sales@advtechind.com
Country
United States
ProdList
6075
Advantage
58
ApexBio Technology
Tel
--
Fax
--
Email
sales@apexbt.com
Country
United States
ProdList
6251
Advantage
58
CarboMer, Inc.
Tel
--
Fax
--
Email
sales@carbomer.com
Country
United States
ProdList
4026
Advantage
67
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81
LC Laboratories
Tel
--
Fax
--
Email
custserv@lclabs.com
Country
United States
ProdList
503
Advantage
50
United States Biological
Tel
--
Fax
--
Email
chemicals@usbio.net
Country
United States
ProdList
6214
Advantage
80
Creative Enzymes
Tel
--
Fax
--
Email
info@creative-enzymes.com
Country
United States
ProdList
6057
Advantage
58
MedChemExpress
Tel
--
Fax
--
Email
sales@medchemexpress.com
Country
United States
ProdList
6398
Advantage
58
Matrix Scientific
Tel
--
Fax
--
Email
sales@matrixscientific.com
Country
United States
ProdList
6632
Advantage
80
TOKU-E Company
Tel
--
Fax
--
Email
info@toku-e.com
Country
United States
ProdList
320
Advantage
50
Fragmenta
Tel
--
Fax
--
Email
sales@fragmenta.com
Country
United States
ProdList
1068
Advantage
0
Santa Cruz Biotechnology, Inc.
Tel
--
Fax
--
Email
scbt@scbt.com
Country
United States
ProdList
3597
Advantage
60
Selleck Chemicals LLC
Tel
--
Fax
--
Email
info@selleckchem.com
Country
United States
ProdList
824
Advantage
60
Waterstone Technology, LLC
Tel
--
Fax
--
Email
sales@waterstonetech.com
Country
United States
ProdList
6786
Advantage
30
AlliChem, LLC
Tel
--
Fax
--
Email
sales@allichemllc.com
Country
United States
ProdList
6516
Advantage
60
Beta Pharma, Inc.
Tel
--
Fax
--
Email
sales@betapharma.com
Country
United States
ProdList
6226
Advantage
60
Altan Corporation
Tel
--
Fax
--
Email
OrderingService@AltanBiochemicals.com
Country
United States
ProdList
1161
Advantage
30
HONEST JOY HOLDINGS LIMITED
Tel
--
Fax
--
Email
sales@honestjoy.cn
Country
United States
ProdList
6675
Advantage
54
AK Scientific, Inc.
Tel
--
Fax
--
Email
sales@aksci.com
Country
United States
ProdList
6347
Advantage
65
APAC Pharmaceutical, LLC
Tel
--
Fax
--
Email
sales@apacpharma.com
Country
United States
ProdList
6322
Advantage
38
American Custom Chemicals Corporation
Tel
--
Fax
--
Email
sales@acccorporation.com
Country
United States
ProdList
6820
Advantage
51
Molcan Corporation
Tel
--
Fax
--
Email
info@molcan.com
Country
United States
ProdList
686
Advantage
60
SynFine Research
Tel
--
Fax
--
Email
research@synfine.com
Country
United States
ProdList
1024
Advantage
68
More
Less

View Lastest Price from Erlotinib manufacturers

WUHAN FORTUNA CHEMICAL CO., LTD
Product
Erlotinib 183321-74-6
Price
US $0.00/Kg/Bag
Min. Order
10g
Purity
99%min
Supply Ability
5000g
Release date
2021-11-03
shandong perfect biotechnology co.ltd
Product
Erlotinib HCl 183321-74-6
Price
US $0.00/g
Min. Order
1g
Purity
98% HPLC
Supply Ability
1kg
Release date
2023-08-02
Baoji Guokang Bio-Technology Co., Ltd.
Product
Erlotinib 183321-74-6
Price
US $415.00/g/Bag
Min. Order
100g
Purity
99%
Supply Ability
10kg
Release date
2021-06-04

183321-74-6, ErlotinibRelated Search:

Triethylamine Glycine 6-Aminocaproic acid Dibenzylamine Anisole Tris(hydroxymethyl)aminomethane Bis(2-ethylhexyl)amine Ethoxyethyne Nilotinib ALTRENOGEST Guaiacol p-Anisaldehyde Imatinib (Trifluoromethoxy)benzene Triallylamine Ethoxyquin 4-Methoxyphenol Gefitinib

  • ERLOTINIB
  • ERLOTINIB HCL
  • ERLOTINIB HCL SALT
  • 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
  • n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
  • Erlotinib Hydrochloirde
  • 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-
  • Tarceva
  • ERLOTININ
  • Erlortinib
  • N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
  • Erlotinib & its intermediates
  • CP-358774, Ro 50-8231
  • Erlotinib Free Base
  • OSI 744
  • R 1415
  • Erlotinib &aMp
  • its interMediates
  • O-desmethyl erlotinib carboxylic acid
  • Erlotinib N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
  • Erlotinib ERLOTINIB
  • Erlotinib (OSI-744)
  • Erlonat
  • Erlotinib (Tarceva)
  • NSC-71878
  • OSI744;CP-358774;NSC-71878;ERLOTINIB HCL (OSI 744;CP358774;NSC718781)
  • Erlotinib USP/EP/BP
  • Erlotinib (OSI744, Tarceva)
  • ErlotinibQ: What is Erlotinib Q: What is the CAS Number of Erlotinib Q: What is the storage condition of Erlotinib Q: What are the applications of Erlotinib
  • Erlotinib 183321-74-6
  • Rotini
  • R-1415CP-358,774
  • Erlotinib (OSI-774)
  • 183321-74-6
  • 83321-74-6
  • Isotope
  • Tarceva
  • Anti-cancer&immunity
  • Antineoplastic
  • Inhibitors
  • API
  • APIs
  • Pharmaceutical intermediate
  • Erlotinib